Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

898 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis.
Lingor P, Weber M, Camu W, Friede T, Hilgers R, Leha A, Neuwirth C, Günther R, Benatar M, Kuzma-Kozakiewicz M, Bidner H, Blankenstein C, Frontini R, Ludolph A, Koch JC; ROCK-ALS Investigators. Lingor P, et al. Front Neurol. 2019 Mar 27;10:293. doi: 10.3389/fneur.2019.00293. eCollection 2019. Front Neurol. 2019. PMID: 30972018 Free PMC article.
Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis-a cross-sectional multicenter study.
Meyer T, Salkic E, Grehl T, Weyen U, Kettemann D, Weydt P, Günther R, Lingor P, Koch JC, Petri S, Hermann A, Prudlo J, Großkreutz J, Baum P, Boentert M, Metelmann M, Norden J, Cordts I, Weishaupt JH, Dorst J, Ludolph A, Koc Y, Walter B, Münch C, Spittel S, Dreger M, Maier A, Körtvélyessy P. Meyer T, et al. Among authors: hermann a. Eur J Neurol. 2023 Jun;30(6):1600-1610. doi: 10.1111/ene.15773. Epub 2023 Mar 26. Eur J Neurol. 2023. PMID: 36899448
Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study.
Günther R, Wurster CD, Brakemeier S, Osmanovic A, Schreiber-Katz O, Petri S, Uzelac Z, Hiebeler M, Thiele S, Walter MC, Weiler M, Kessler T, Freigang M, Lapp HS, Cordts I, Lingor P, Deschauer M, Hahn A, Martakis K, Steinbach R, Ilse B, Rödiger A, Bellut J, Nentwich J, Zeller D, Muhandes MT, Baum T, Christoph Koch J, Schrank B, Fischer S, Hermann A, Kamm C, Naegel S, Mensch A, Weber M, Neuwirth C, Lehmann HC, Wunderlich G, Stadler C, Tomforde M, George A, Groß M, Pechmann A, Kirschner J, Türk M, Schimmel M, Bernert G, Martin P, Rauscher C, Meyer Zu Hörste G, Baum P, Löscher W, Flotats-Bastardas M, Köhler C, Probst-Schendzielorz K, Goldbach S, Schara-Schmidt U, Müller-Felber W, Lochmüller H, von Velsen O; SMArtCARE Study Group; Kleinschnitz C, Ludolph AC, Hagenacker T. Günther R, et al. Among authors: hermann a. Lancet Reg Health Eur. 2024 Feb 6;39:100862. doi: 10.1016/j.lanepe.2024.100862. eCollection 2024 Apr. Lancet Reg Health Eur. 2024. PMID: 38361750 Free PMC article.
A 3D cell culture system for bioengineering human neuromuscular junctions to model ALS.
Massih B, Veh A, Schenke M, Mungwa S, Seeger B, Selvaraj BT, Chandran S, Reinhardt P, Sterneckert J, Hermann A, Sendtner M, Lüningschrör P. Massih B, et al. Among authors: hermann a. Front Cell Dev Biol. 2023 Feb 14;11:996952. doi: 10.3389/fcell.2023.996952. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 36866276 Free PMC article.
Targeting low levels of MIF expression as a potential therapeutic strategy for ALS.
Alfahel L, Gschwendtberger T, Kozareva V, Dumas L, Gibbs R, Kertser A, Baruch K, Zaccai S, Kahn J, Thau-Habermann N, Eggenschwiler R, Sterneckert J, Hermann A, Sundararaman N, Vaibhav V, Van Eyk JE, Rafuse VF, Fraenkel E, Cantz T, Petri S, Israelson A. Alfahel L, et al. Among authors: hermann a. Cell Rep Med. 2024 Apr 29:101546. doi: 10.1016/j.xcrm.2024.101546. Online ahead of print. Cell Rep Med. 2024. PMID: 38703766 Free article.
PROSA-a multicenter prospective observational study to develop low-burden digital speech biomarkers in ALS and FTD.
Tröger J, Baltes J, Baykara E, Kasper E, Kring M, Linz N, Robin J, Schäfer S, Schneider A, Hermann A. Tröger J, et al. Among authors: hermann a. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Jul 30:1-10. doi: 10.1080/21678421.2023.2239312. Online ahead of print. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 37516990
In-depth analysis of data from the RAS-ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis.
Schuster J, Dreyhaupt J, Mönkemöller K, Dupuis L, Dieterlé S, Weishaupt JH, Kassubek J, Petri S, Meyer T, Grosskreutz J, Schrank B, Boentert M, Emmer A, Hermann A, Zeller D, Prudlo J, Winkler AS, Grehl T, Heneka MT, Johannesen S, Göricke B, Witzel S, Dorst J, Ludolph AC; RAS-ALS Study Group. Schuster J, et al. Among authors: hermann a. Eur J Neurol. 2024 Apr;31(4):e16204. doi: 10.1111/ene.16204. Epub 2024 Jan 19. Eur J Neurol. 2024. PMID: 38240416 Clinical Trial.
898 results